COPD chronic obstructive pulmonary

COPD, chronic obstructive pulmonary disease EAE, experimental autoimmune encephalomyelitis RSV, respiratory syncytial virus SLE, systemic lupus erythematosus. 

Con A Concanavalin A COPD Chronic obstructive pulmonary disease COS Fibroblast-like kidney cell line established from simian cells CoVF Cobra venom CP Creatine phosphate Cp Caeruloplasmin c.p.m. Counts per minute CPJ Cartilage/pannus junction Cr The chemical symbol fir chromium CR Complement receptor CRl, CR2 CR4 Complement receptor types 1, 2 and 4 CR3-a Complement receptor type 3-[Pg.281]

COPD, chronic obstructive pulmonary disease CVA, cerebrovascular accident. 

COPD Chronic obstructive pulmonary disease EENT Eyes, ears, nose, throat... 

CHF congestive heart failure CHI closed head injury CLA cis-linoleic acid CLL chronic lymphocytic leukemia CML chronic myelogenous leukemia CMV cytomegalovirus CNS central nervous system Comps complications COMT catechol-O-methyltransferase Contra contraindicated COPD chronic obstructive pulmonary disease COX cyclooxygenase CP chest pain... 

AChE, acetylcholinesterase CNS, central nervous system COPD, chronic obstructive pulmonary disease. PREPARATIONS AVAILABLE Antimuscarinic Anticholinergic Drugs ... 

Table 10.1 Drags administered by inhalation for local action in the airways. COPD=chronic obstructive pulmonary disease CF=cystic fibrosis...

The defining structural element found in rolipram and its relatives is the dialkoxyphenyl (catechol) moiety. Although the development of rolipram (then for depression) was terminated early, many companies have since disclosed PDE4 inhibitors intended primarily for indications such as asthma and COPD (chronic obstructive pulmonary disease) [58], For a long time, cilomilast (Ariflo, 54) has appeared to be ahead in this race [59], In November 2003, GSK received an approvable letter from the FDA, despite the FDA advisory panel s earlier negative opinion of the compound. The extent to which new studies may have been requested by the FDA and will delay approval remains to be seen. 

Key M male F female DM diabetes mellltus HTN hypertension CAD coronary artery disease COPD chronic obstructive pulmonary disease CHF congestive heart failure ESRD end stage renal disease OSPS oral sodium phosphate solution PEG polyethylene glycol AKI acute kidney Injury na not available HD hemodialysis. 

COPD chronic obstructive pulmonary disease E217 p G estradiol-17 p -D-glucuronide... 

ALL allergies COPD chronic obstructive pulmonary disease... 

Severe COPD (chronic obstructive pulmonary disease) Initial 250 ml of 0.15 percent, which caused significant alveolar debridement and coughing up of copious amount of purulent material. Continued weekly infusions for six weeks, and by the end of the sixth treatment, the patient no longer was coughing. Comment Pulmonary function improved and the patient returned to working full-time. Maintained on treatment according to patient s "feel the need," which recurs approximately every four to six weeks. 

G6PD, Glucose-6-phosphate dehydrogenase BA, bioavailability COPD Chronic Obstructive Pulmonary Disease. 

COPD chronic obstructive pulmonary disease Dlco diffusion capacity for carbon monoxide DPI dry powder inhaler FEVi forced expiratory volume in 1 second FVC forced vital capacity... 

ACE angiotensin-converting enzyme CNS central nervous system COPD chronic obstructive pulmonary disease DPIs dry-powder inhalers EDTA ethylenediamine tetraacetic acid EDA Eood and Drug Administration EEVi forced expiratory volume in 1 second HIV human immunodeficiency virus IPS idiopathic pneumonia syndrome NSAIDs nonsteroidal anti-inflammatory drugs... 

---